The discovery of the ninth member of the proprotein convertase family, proprotein convertase subtilisin kexin 9 (i.e. PCSK9) in 2003 by Seidah et al. 1 triggered an extraordinary research race, which in the same year confirmed the important role of PCSK9 for low-density lipoprotein (LDL) regulation in two French families with familial hypercholesterolemia and a gain-offunction (GOF) mutation of the PCSK9 gene. 2 In the following years several other PCSK9 gene mutations were identified, both GOF mutations with mild to severe hypercholesterolemia 3 and loss-of-function (LOF) mutations. 4, 5 The potential clinical implications of decreasing LDL through PCSK9 inhibition soon led to several community-based cohort studies, which examined the association between PCSK9 LOF mutations, LDL concentration and cardiovascular events. In African Americans the LOF mutations Y142X and C679X led to a 28% reduction in LDL-cholesterol and an 88% reduction in the risk of coronary heart disease. In Caucasians the R46L LOF mutation was associated with a 15% reduction in LDL-cholesterol and a 47% reduction in the risk of coronary artery disease (CAD). 5 In a meta-analysis of three Danish studies of carriers of the R46L LOF mutation a 12% reduction in LDL-cholesterol resulted in a 28% reduction in CAD. 6 The identification of PCSK9 as a pharmacological target for effective LDL-cholesterol reduction brought about the fastest drug development race in modern medical history. After successful completion of the first phase III clinical trials, two human monoclonal antibodies against PCSK9 were approved for clinical use in 2016 -just 13 years after the first description of the protein: evolocumab and alirocumab. The first prospective outcome trial -the Fourier study -confirmed the clinical efficacy of evolocumab in 27,564 high-risk, stable patients with established cardiovascular disease and LDL-cholesterol of 70 mg/dL or greater or non-high-density lipoprotein (HDL)-cholesterol of 100 mg/dL or greater under uptitrated statin therapy with or without ezetimibe. 7 Subcutaneous administration of evolocumab 140 mg every 2 weeks reduced LDL-cholesterol by 59% and reduced the primary endpoint (cardiovascular death, myocardial infarction, stroke, hospitalisation for unstable angina, or coronary revascularisation) from 14.6% to 12.6% over 3 years (relative risk reduction À15%, P < 0.0001). 8 The results of the second large outcome study with alirocumab -the Odyssey Outcomes trial -will be presented in March 2018 and the cardiology community is eager to see whether the major adverse cardiac event reduction seen in Fourier will also lead to a mortality reduction. 9 Cardiovascular medicine is at a threshold to a new era. Ultra-low LDL-cholesterol reduction using PCSK9 inhibitors promises clinical effects previously only dreamt of: in the GLAGOV study ultra-low LDLcholesterol of 36.6 mg/dL resulted in significant plaque regression in patients with stable CAD. 10 New methods of long-term PCSK9 inhibition are being developed including siRNA approaches (inclisiran) 11 and anti-PCSK9 vaccinations. 12 Given the momentum of these novel developments we may soon expect large numbers of patients to be started on long-term PCSK9 inhibition -first those with familial hypercholesterolemia, then patients with manifest cardiovascular disease not at LDL-cholesterol target despite high-dose statin therapy. With vaccination around the corner one could even envisage anti-PCSK9 vaccination of young adults for primary prevention to eradicate cardiovascular disease in the future.
Brave new worlds should always be carefully assessed before we bet on them. There are still a lot of open questions with long-term PCSK9 inhibition:
. Will there be any adverse effects with long-term exposure to ultra-low LDL-cholesterol levels regarding neurocognitive function? So far, safety data from the existing trials are reassuring. In the large Ebbinghaus study a subgroup of 1204 patients from Fourier were followed for a median of 19 months and showed no decline in cognitive function. 13 These data of ectopic fat accumulation were confirmed in an animal model of PCSK9 knock-out mice, which showed 50% increased visceral adipose tissue accumulation versus wild type mice.
The findings of Baragetti et al. are highly relevant for the future clinical application of PCKS9 inhibitors in thousands of patients: there data are consistent with previously published reports that PCSK9 targets not only the hepatic LDL receptor but also the very LDL receptor and ApoE2 receptor 7. 14 The very LDL receptor has been shown to modulate the extrahepatic metabolism of triglyceride-rich lipoproteins (TGRLs) and the delivery of fatty acids to peripheral tissues. Although the authors are careful enough to state that 'it is unknown whether the observed effect on ectopic fat accumulation is peculiar for genetically determined low levels of PCSK9 or whether it might occur also in patients treated with anti-PCSK9 mAbs' they are to be congratulated on highlighting future safety endpoints for long-term PCSK9 inhibitor studies: visceral and ectopic fat accumulation and the metabolism of TGRLs. This is especially relevant because visceral fat has been shown to have endocrine activity through the release of adipokines (e.g. leptin), which influence energy and glucose metabolism and are involved in the metabolic syndrome. 15, 16 Until now there is no safety signal from PCSK9 studies that the incidence of diabetes is increased in patients treated with alirocumab and evolocumab. However, we need longer observation periods to be certain.
Alirocumab and evolocumab may be close to 100% specific for PCSK9 inhibition, but the biological effects of PCSK9 itself are not limited to the hepatic LDL receptor recycling. Before widespread clinical application secondary actions of PCSK9 need to be fully elucidated and evaluated to anticipate potential adverse effects of PCSK9 inhibition.
Finally, the finding of pathological fat redistribution in individuals with PCSK9 LOF mutations calls for our sustained efforts to implement comprehensive lifestyle changes in secondary prevention, including a healthy diet, weight normalisation and regular exercise. Even novel drugs such as PCSK9 inhibitors will not substitute the need for a healthy lifestyle to achieve optimal risk profiles in secondary prevention.
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